Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID.

ABSTRACT:

Objectives

Methotrexate (MTX) is one of the most commonly used medications to treat rheumatoid arthritis (RA). However, the effect of MTX treatment on cellular immune responses remains incompletely understood. This raises concerns about the vulnerability of these patients to emerging infections and following vaccination.

Methods

In the current study, we investigated the impact of MTX treatment in patients with immune-mediated inflammatory disease on B and CD4 T cell SARS-CoV-2 vaccination responses. Eighteen patients with RA and two patients with psoriatic arthritis on MTX monotherapy were included, as well as 10 patients with RA without immunosuppressive treatment, and 29 healthy controls. CD4 T and B cell responses were analysed 7 days and 3-6 months after two SARS-CoV-2 m

SUBMITTER: Kummer LYL 

PROVIDER: S-EPMC11459311 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature